Spruce Biosciences

Tralesinidase alfa enzyme replacement therapy (TA-ERT) demonstrated profound and durable efficacy over five years in 22 patients with Sanfilippo Syndrome Type B, significantly reducing pathogenic biomarkers to normal levels.

HMNC Brain Health and Spruce Biosciences have dosed the first patient in the Phase 2 TAMARIND trial, evaluating tildacerfont as a precision treatment for major depressive disorder.

Spruce Biosciences has acquired tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B, a neurodegenerative and fatal genetic disease with no FDA-approved treatments.

• The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH). • Crinecerfont, a selective CRF1 receptor antagonist, aims to manage ACTH and androgen levels without glucocorticoids, potentially revolutionizing CAH treatment. • If approved, crinecerfont would be the first new CAH treatment in 70 years, offering a novel mechanism to address this rare endocrine disorder. • The CAH market is expected to grow significantly, driven by emerging therapies like crinecerfont, with a projected CAGR of ~40% to reach USD 20 billion by 2034.